leadf
logo-loader
viewMaxCyte Inc

Maxcyte to present clinical data from MCY-M11 phase one trial at American Society of Clinical Oncology

The data encompasses the first three cohorts of a dose escalation trial to demonstrate the safety of MCY-M11 and the feasibility of one-day manufacturing

MaxCyte Inc - Maxcyte to present clinical data from MCY-M11 phase one trial at the American Society of Clinical Oncology

MaxCyte Inc (LON:MXCT) has said it will present clinical data from an ongoing phase one trial of its MCY-M11 treatment for ovarian cancer and peritoneal mesothelioma at the American Society of Clinical Oncology's upcoming annual meeting.

The cell-based therapy specialist said the data, which encompasses the first three cohorts of a dose-escalation trial to demonstrate the safety of MCY-M11 and the feasibility of one-day manufacturing, will be available as a poster presentation in the Developmental Therapeutics: Immunotherapy session from 8am Eastern Time (1pm BST) on May 29.

WATCH: MaxCyte deal with Caribou 'demonstrates expertise and value' of its Flow Electroporation technology

The presentation will be entitled: "Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma."

The third cohort began dosing in the MCY-M11 trial in October 2019, while a fourth cohort commenced dosing in March this year.

Preliminary clinical results for the trial are expected to be announced in the second half of 2020.

MaxCyte shares rose 2.9% to 180p in early deals on Thursday.

Quick facts: MaxCyte Inc

Price: 410 GBX

AIM:MXCT
Market: AIM
Market Cap: £316.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 18/8/20

2 min read